Immunic, Inc. (NASDAQ:IMUX – Get Free Report) has received a consensus rating of “Buy” from the nine brokerages that are ...

Immunic, Inc. to Participate in Scientific and Industry Conferences in April ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...

Immunic (IMUX – Research Report) received a Buy rating and a $1.20 price target from William Blair analyst Matt Phipps yesterday. The company’s ...

Analysts at William Blair issued their FY2026 EPS estimates for shares of Immunic in a research note issued to investors on ...

Lundin Mining Announces New Shareholder Distribution Policy; Adjusting Quarterly Dividend to C$0.0275/Share From C$0.09/Share; Allocating Up to Around $150M Per Year in Share Buybacks; Committed to ...

Fintel reports that on March 25, 2025, William Blair initiated coverage of Immunic (NasdaqGS:IMUX) with a Outperform ...

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com ...

A person walks in front of an electronic stock board showing Japan's Nikkei index at a securities firm Thursday, March 6, 2025, in Tokyo. A person walks in front of an electronic stock board ...

Avec Les Echos suivez en temps réel toute l'actualité financière puisée aux meilleures sources des sociétés cotées sur les bourses de Paris, Bruxelles, Amsterdam, Lisbonne, Francfort et New York.

NEW YORK, March 3, 2025 – Immunic , Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and ...